Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
- Referrals to patient-related programs or resources
- Donations, website, or event-related assistance
- Tobacco-related topics
- Volunteer opportunities
- Cancer Information
For medical questions, we encourage you to review our information with your doctor.
Research We Fund: Extramural Discovery Science
- Discovery Boost Grants (DBG)
- Arizona (AZ) Discovery Boost Grants (DBG)
- Mission Boost Grants (MBG)
- Research Scholar Grants
- Postdoctoral Fellowships
- Clinician Scientist Development Grant (CSDG)
- ASTRO-ACS Clinician Scientist Development Grant (CSDG)
- Institutional Research Grants
- RFA: Leukemia Exploration and Prevention Grant Program (LEAP)
- RFA: ACS IMPACT - Expanding Prostate Cancer Clinical Trials in the Community
- RFA: Extramural Discovery Science Accelerator Award
- RFA: Cancer Health Equity Research Centers
- IMPACT RFA to Support Research to Reduce Prostate Cancer Mortality
- TheoryLab Collaborative (TLC) Grant
- RFA: The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services
- ACS Professor Award
- Extramural Grants Department Staff Contacts
- Definition of Research Areas
- FAQs: ACS Extramural Discovery Science and Grant Application Submissions
- Extramural Priority Research Areas
- Our Grant Process
- American Cancer Society Research Events
- Peer Review Committee for DNA Mechanisms in Cancer (DMC)
- Peer Review Committee for Immunology and Blood Cell Development (IBCD)
- Peer Review Committee for RNA Mechanisms in Cancer (RMC)
- Peer Review Committee for Tumor Biochemistry and Endocrinology (TBE)
- Peer Review Committee for Cancer Cell Biology (CCB)
- Peer Review Committee for Cancer Detection and Progression (CDP)
- Peer Review Committee for Experimental Therapeutics (ET)
- Peer Review Committee for Metastasis and Microenvironment (MM)
- Peer Review Committee for Cancer Prevention and Health Promotion (CPHP)
- Peer Review Committee for Treatment, Palliative Care, and Survivorship Research
- Peer Review Committee for Etiology, Screening, and Early Detection (ESED)
- Peer Review Committee for Healthcare Outcomes, Policy, and Systems Research (HOPS)
- ACS Professor Peer Review Committee
- Peer Review Committee for Institutional Research Grants (IRG)
- Molecular Biology and Biochemistry (PF-MBB)
- Cell Biology and Immunology (PF-CBI)
- Cancer Detection and Experimental Therapeutics (PF-CDET)
- Clinical and Population Sciences (PF-CPS)
- Peer Review Committee for Mission Boost Grants
- Discovery Scientific Council
- Community Research Partner Participation on Grant Peer Review Committees
- American Cancer Society Professors
- Nobel Laureates and the American Cancer Society
RFA: Extramural Discovery Science Accelerator Award
The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful. Examples of research that align with the focus of this funding initiative include but are not limited to:
- Dosing, toxicity and/or efficacy testing
- Testing of biopsies or other patient samples to correlate clinical outcome
- Technologies for healthcare delivery
Accelerator awardees will become part of an entrepreneurial collaborative learning community focused on technology commercialization. Grantees will have access to both educational programming developed by the ACS BrightEdge team and the team itself.
Eligibility
Applicants must:
- Be a current or former ACS grantee (includes IRG pilot grant awardees) or a former ACS postdoctoral fellow.
- Have a full-time faculty appointment, at an eligible US institution. Applicants may be at any career stage.
- Be motivated to commercialize their technology.
Grant Budget and Term
Budgets can be up to $75,000 total costs for a one-year term. Indirect costs are not allowed.
Application and Review Process
Applications will be accepted on a rolling basis during the year (i.e., no set deadline).
Timeline:
- Applications submitted by April 30, 2024, will be reviewed in May 2024. Applications submitted May 1 to August 31, 2024, will be reviewed in September 2024.
- Grants start in August 2024 (May review) or March 2025 (September review).
Application materials are available on ProposalCentral. Applicants will have 1 month from starting the application to submit it in ProposalCentral. Please see the application instructions for detailed guidelines.
Program Contact: Doug Hurst, PhD at doug.hurst@cancer.org